Tumor malignancy as the possible acquisition of markers of trophoblastic ontogeny: preliminary in vitro and in ovo study
Metadata
Show full item recordAuthor
Chico Lozano, María Ángeles; Doello, Kevin; Mesas Hernández, Cristina; Quiñonero Muñoz, Francisco José; Perazzoli, Gloria; Melguizo Alonso, Consolación; Ortiz Quesada, Raúl; Prados Salazar, José CarlosEditorial
Sociedad Española de Anatomía
Materia
Trophoblast Cancer Trophoblastic markers
Date
2025-07-04Referencia bibliográfica
Chico, M. Á., Doello, K., Mesas, C., Quiñonero, F., Perazzoli, G., Melguizo, C., Ortiz, R., & Prados, J. (2025). Tumor malignancy as the possible acquisition of markers of trophoblastic ontogeny: Preliminary in vitro and in ovo study. European Journal of Anatomy, 29(4), 469-479. https://doi.org/10.52083/HVCH9041
Sponsorship
Ministerio de Universidades (Spain), FPU21/05109Abstract
Trophoblastic and tumor cells share behaviors such as invasiveness, angiogenesis, immune scape, chemoresistance and survival to hostile environments, suggesting that some types of cancer could be a transformation to a trophoblastic phenotype. This hypothesis exposes that the expression of some trophoblastic markers can be correlated with tumor malignancy. The expression
of trophoblastic markers (TBX3, TBX2, ERVW1, HLAG and Trop2) and tumor aggressiveness (MMP9, MMP2, VEGF and TGF-β) was evaluated by RT-pPCR in different tumor cell lines. Biotinidase activity was also studied. In addition, tumors were induced in chicken chorioallantoic membrane to analyze morphology, tumor area and clonogenicity. Overexpression of two or more trophoblastic markers was identified in SF268, MG63, A549, HT29, HCT15 and Skbr3. The results correlated with aggressiveness and invasiveness in the in ovo assay. In addition, these tumor cell lines showed higher biotinidase activity so they can survive the
lack of biotin cofactor. The overexpression of trophoblasticmmarkers was correlated with the presence of a malignant phenotype characterized by aggressiveness, invasiveness, clonogenicity and resistance to the lack of cofactors such as biotin. These markers could be used in the early diagnosis and prognosis of some types of cancer and in the development of new therapeutic strategies.





